Table 4.
DIANA-miRPath GO category enrichment results
| GO category | P-value | miRNAs | Number of target genes |
|---|---|---|---|
| Biosynthetic process | 2.05(E-12) | hsa-miR-6732-3p hsa-miR-5001-5p | 219 |
| Cellular nitrogen compound metabolic process | 3.01(E-11) | hsa-miR-6732-3p hsa-miR-5001-5p hsa-miR-4257 | 298 |
| Cellular protein modification process | 1.15(E-06) | hsa-miR-6732-3p hsa-miR-5001-5p | 130 |
| Gene expression | 8.07(E-05) | hsa-miR-6732-3p hsa-miR-5001-5p | 42 |
| Viral process | 1.20(E-03) | hsa-miR-6732-3p hsa-miR-5001-5p | 36 |
| Symbiosis, encompassing mutualism through parasitism | 1.52(E-03) | hsa-miR-6732-3p hsa-miR-5001-5p | 38 |
| Epidermal growth factor receptor signalling pathway | 4.38(E-03) | hsa-miR-6732-3p | 10 |
| Transcription, DNA templated | 5.24(E-03) | hsa-miR-6732-3p hsa-miR-5001-5p | 139 |
| Neurotrophin TRK receptor signalling pathway | 5.87(E-03) | hsa-miR-6732-3p | 10 |
| Catabolic process | 7.60(E-03) | hsa-miR-5001-5p | 70 |
| Fc-epsilon receptor signalling pathway | 9.99(E-03) | hsa-miR-6732-3p | 8 |
| Cellular protein metabolic process | 1.77(E-02) | hsa-miR-6732-3p hsa-miR-4788 | 14 |
| Blood coagulation | 3.11(E-02) | hsa-miR-4788 hsa-miR-5001-5p | 21 |
| Small molecule metabolic process | 3.14(E-02) | hsa-miR-5001-5p | 75 |